CA2106464A1 - Vaccin anti-poxvirus recombine avec de l'adn de plasmodium - Google Patents
Vaccin anti-poxvirus recombine avec de l'adn de plasmodiumInfo
- Publication number
- CA2106464A1 CA2106464A1 CA002106464A CA2106464A CA2106464A1 CA 2106464 A1 CA2106464 A1 CA 2106464A1 CA 002106464 A CA002106464 A CA 002106464A CA 2106464 A CA2106464 A CA 2106464A CA 2106464 A1 CA2106464 A1 CA 2106464A1
- Authority
- CA
- Canada
- Prior art keywords
- sera
- poxvirus
- vaccinia
- vaccine
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000004792 malaria Diseases 0.000 title description 22
- 229940024231 poxvirus vaccine Drugs 0.000 title description 3
- 241000224016 Plasmodium Species 0.000 claims abstract description 31
- 229960005486 vaccine Drugs 0.000 claims abstract description 30
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 29
- 241000178270 Canarypox virus Species 0.000 claims abstract description 14
- 230000028993 immune response Effects 0.000 claims abstract description 13
- 230000002238 attenuated effect Effects 0.000 claims abstract description 8
- 230000001018 virulence Effects 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 108020004414 DNA Proteins 0.000 claims description 55
- 241000223960 Plasmodium falciparum Species 0.000 claims description 47
- 241000517645 Abra Species 0.000 claims description 44
- 108091026890 Coding region Proteins 0.000 claims description 35
- 101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 claims description 33
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims description 23
- 101150078331 ama-1 gene Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 4
- 208000020997 susceptibility to multiple system atrophy 1 Diseases 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract description 74
- 208000007089 vaccinia Diseases 0.000 abstract description 74
- 239000013612 plasmid Substances 0.000 description 107
- 239000012634 fragment Substances 0.000 description 103
- 239000002299 complementary DNA Substances 0.000 description 73
- 238000003780 insertion Methods 0.000 description 47
- 230000037431 insertion Effects 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 44
- 239000013598 vector Substances 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 41
- 102100021516 Actin-binding Rho-activating protein Human genes 0.000 description 40
- 101000677807 Homo sapiens Actin-binding Rho-activating protein Proteins 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 26
- 230000036961 partial effect Effects 0.000 description 25
- 239000002773 nucleotide Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 230000006798 recombination Effects 0.000 description 24
- 244000045947 parasite Species 0.000 description 23
- 101100119854 Candida albicans FCR3 gene Proteins 0.000 description 22
- 238000005215 recombination Methods 0.000 description 22
- 238000001114 immunoprecipitation Methods 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 241000700605 Viruses Species 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 210000003046 sporozoite Anatomy 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000036039 immunity Effects 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000001563 schizont Anatomy 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 210000003936 merozoite Anatomy 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108020004635 Complementary DNA Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 6
- 241000255925 Diptera Species 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000000078 anti-malarial effect Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
- 230000005030 transcription termination Effects 0.000 description 6
- 101150052200 CS gene Proteins 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010185 immunofluorescence analysis Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 238000012809 post-inoculation Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 241000700663 Avipoxvirus Species 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101100352308 Plasmodium knowlesi (strain nuri) PK66 gene Proteins 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 108010000222 polyserine Proteins 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000003812 trophozoite Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 101150001566 ABRA gene Proteins 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 3
- 108010005843 Cysteine Proteases Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 101150039660 HA gene Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010037742 Rabies Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 239000003430 antimalarial agent Substances 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- -1 carboxy- Chemical class 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 2
- 241000256186 Anopheles <genus> Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- 241000223801 Plasmodium knowlesi Species 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- VHUBNUSXPIJYSG-QIRCYJPOSA-N [(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl] dihydrogen phosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(O)=O VHUBNUSXPIJYSG-QIRCYJPOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000973 gametocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229940124735 malaria vaccine Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000012808 pre-inoculation Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000037972 tropical disease Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 description 1
- 101710189301 101 kDa malaria antigen Proteins 0.000 description 1
- 101150076401 16 gene Proteins 0.000 description 1
- 101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 description 1
- 101100156317 Arabidopsis thaliana VIP1 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001436672 Bhatia Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 101000849787 Brucella melitensis biotype 1 (strain 16M / ATCC 23456 / NCTC 10094) Ribosome-recycling factor Proteins 0.000 description 1
- 101000871494 Caenorhabditis elegans m7GpppX diphosphatase Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001062872 Cleyera japonica Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 102100037364 Craniofacial development protein 1 Human genes 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101000880187 Homo sapiens Craniofacial development protein 1 Proteins 0.000 description 1
- 101000855342 Homo sapiens Cytochrome P450 1A2 Proteins 0.000 description 1
- 101000745891 Homo sapiens Cytochrome P450 26A1 Proteins 0.000 description 1
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241001024099 Olla Species 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 241000223980 Plasmodium falciparum NF54 Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001080189 Quadrus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 101150002000 hsp-3 gene Proteins 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000000054 macrogamete Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001046 rapid expansion of supercritical solution Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000017259 schizogony Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241000700570 unidentified entomopoxvirus Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67218391A | 1991-03-20 | 1991-03-20 | |
| US672,183 | 1991-03-20 | ||
| US85230592A | 1992-03-18 | 1992-03-18 | |
| US852,305 | 1992-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2106464A1 true CA2106464A1 (fr) | 1992-09-21 |
Family
ID=27100699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002106464A Abandoned CA2106464A1 (fr) | 1991-03-20 | 1992-03-19 | Vaccin anti-poxvirus recombine avec de l'adn de plasmodium |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0575544A4 (fr) |
| JP (1) | JPH06505397A (fr) |
| AU (3) | AU674491B2 (fr) |
| CA (1) | CA2106464A1 (fr) |
| WO (1) | WO1992016616A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217898A (en) * | 1988-05-02 | 1993-06-08 | The United States Of America As Represented By The Secretary Of Health And Human Services | Expression of the P. falciparum transmission-blocking antigen in yeast |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| DE19640817A1 (de) * | 1996-10-02 | 1998-05-14 | Hermann Prof Dr Bujard | Rekombinantes Herstellungsverfahren für ein vollständiges Malaria-Antigen gp190/MSP 1 |
| WO1999007869A1 (fr) * | 1997-08-05 | 1999-02-18 | University Of Florida | Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite |
| US7198791B2 (en) | 2003-03-03 | 2007-04-03 | Pluschke, Gerd Et Al. | Compositions and methods for the generation of protective immune responses against malaria |
| EP2818175B1 (fr) * | 2009-05-05 | 2018-11-21 | Cadila Healthcare Limited | Vaccin combiné rougeole-malaria |
| AU2014374198A1 (en) * | 2013-12-30 | 2016-08-11 | V-Core Technologies, Inc. | Poxvirus-Plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using same |
| WO2018237339A1 (fr) * | 2017-06-22 | 2018-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Vaccin contre le paludisme utilisant du plasmodium à base de nyvac |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| AU613970B2 (en) * | 1987-10-09 | 1991-08-15 | Motorola, Inc. | Radio arrangement having two radios sharing circuitry |
| CA1341245C (fr) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Virus recombinant de la vaccine derive du virus modifie ankara |
| WO1990001549A2 (fr) * | 1988-08-12 | 1990-02-22 | Trustees Of Dartmouth College | Genes de codage des antigenes proteiniques du plasmodium falciparum |
| IE71643B1 (en) * | 1990-11-20 | 1997-02-26 | Virogenetics Corp | A recombinant poxviral vaccine for canine distemper |
| AU1588092A (en) * | 1991-02-22 | 1992-09-15 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Transmission blocking vaccine against malaria |
| KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| WO1992022641A1 (fr) * | 1991-06-14 | 1992-12-23 | Virogenetics Corporation | Vaccin a base de poxvirus recombine comprenant le virus de l'immunodeficience |
-
1992
- 1992-03-19 EP EP92909302A patent/EP0575544A4/en not_active Withdrawn
- 1992-03-19 JP JP4508824A patent/JPH06505397A/ja active Pending
- 1992-03-19 CA CA002106464A patent/CA2106464A1/fr not_active Abandoned
- 1992-03-19 WO PCT/US1992/002207 patent/WO1992016616A1/fr not_active Application Discontinuation
- 1992-03-19 AU AU16657/92A patent/AU674491B2/en not_active Expired
-
1997
- 1997-04-02 AU AU16680/97A patent/AU1668097A/en not_active Abandoned
- 1997-04-02 AU AU16681/97A patent/AU709479B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU709479B2 (en) | 1999-08-26 |
| AU1668197A (en) | 1997-06-12 |
| EP0575544A1 (fr) | 1993-12-29 |
| AU1665792A (en) | 1992-10-21 |
| JPH06505397A (ja) | 1994-06-23 |
| AU1668097A (en) | 1997-06-12 |
| AU674491B2 (en) | 1997-01-02 |
| EP0575544A4 (en) | 1997-05-21 |
| WO1992016616A1 (fr) | 1992-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5766597A (en) | Malaria recombinant poxviruses | |
| Tine et al. | NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria | |
| Doolan et al. | Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. | |
| Moelans et al. | A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites | |
| US5756101A (en) | Malaria recombinant poxvirus | |
| US5814617A (en) | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene | |
| US6551586B1 (en) | Malaria vaccine based upon the addition of a MSA1 peptide | |
| Black et al. | The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite | |
| AU709479B2 (en) | Recombinant attentuated canrypox ALVAC virus expression vectors containing heterologous DNA segments encoding malarial gene products | |
| US5403581A (en) | Coccidiosis vaccines | |
| JP3215692B2 (ja) | 組み換えコクシジウム症ワクチン | |
| Hedstrom et al. | In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines. | |
| Collins et al. | Studies on the Salvador I strain of Plasmodium vivax in non-human primates and anopheline mosquitoes | |
| EP0584201A1 (fr) | Vaccin de blocage de transmission contre le paludisme | |
| US5393523A (en) | Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II | |
| US6008342A (en) | DNA encoding eimeria antigen | |
| WO2001055181A2 (fr) | Vaccins anti-paludeens multivalents recombines contre plasmodium vivax | |
| Moelans | Pfs16, a potential vaccine candidate against the human malaria parasite Plasmodium falciparum | |
| Tine et al. | Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus | |
| Sandhu et al. | Expression of the merozoite surface protein gp195 in vaccinia virus | |
| IE910966A1 (en) | Plasmodium Sporozoite Antigen | |
| ES2431613T3 (es) | Vacunas contra la malaria basadas en virus recombinante | |
| CZ277921B6 (en) | Peptides and polypeptides, vaccines and nucleic acids | |
| Nardin | 16 Synthetic Peptides as Malaria Vaccines | |
| Semenya | Merozoite invasion of erythrocytes: Revealing functional characteristics of the Plasmodium knowlesi Normocyte Binding Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |